Ajanta Total Revenue vs Long Term Debt Analysis

AJANTPHARM

3,027 30.05 1.00%

Ajanta Pharma financial indicator trend analysis is way more than just evaluating Ajanta Pharma Limited prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ajanta Pharma Limited is a good investment. Please check the relationship between Ajanta Pharma Total Revenue and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajanta Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Total Revenue vs Long Term Debt

Total Revenue vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ajanta Pharma Limited Total Revenue account and Long Term Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Ajanta Pharma's Total Revenue and Long Term Debt is -0.8. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Ajanta Pharma Limited, assuming nothing else is changed. The correlation between historical values of Ajanta Pharma's Total Revenue and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Ajanta Pharma Limited are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Revenue i.e., Ajanta Pharma's Total Revenue and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.8

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Revenue

Total revenue comprises all receipts Ajanta Pharma Limited generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Long Term Debt

Long-term debt is a debt that Ajanta Pharma Limited has held for over one year. Long-term debt appears on Ajanta Pharma Limited balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Ajanta Pharma Limited balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Ajanta Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ajanta Pharma Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajanta Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

The Ajanta Pharma's current Selling General Administrative is estimated to increase to about 9.5 B, while Tax Provision is projected to decrease to under 2 B.

	2021	2022	2023	2024 (projected)
Interest Expense	102M	58.4M	72.1M	83.5M
Depreciation And Amortization	1.2B	1.3B	1.4B	1.4B

Interest Expense Depreciation And Amortization

Ajanta Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Retained Earnings	Net Receivables	Intangible Assets	Accounts Payable	Short Term Debt	Other Liab	Net Tangible Assets
Total Assets		-0.65	0.7	0.94	1.0	0.97	-0.85	0.73	0.98	0.27	0.88	-0.58	0.61	0.98	0.29	-0.29	0.94	0.99	0.72	0.97	0.92	0.14	0.91	-0.65	0.97	0.93
Short Long Term Debt Total	-0.65		-0.37	-0.47	-0.7	-0.7	0.69	-0.39	-0.7	-0.3	-0.57	0.25	-0.12	-0.59	-0.02	-0.03	-0.44	-0.6	-0.46	-0.59	-0.58	-0.07	-0.53	0.9	-0.55	-0.68
Other Current Liab	0.7	-0.37		0.84	0.64	0.57	-0.64	0.61	0.59	0.12	0.82	-0.45	0.67	0.74	-0.12	-0.06	0.84	0.76	0.6	0.75	0.63	0.19	0.66	-0.49	0.7	0.6
Total Current Liabilities	0.94	-0.47	0.84		0.9	0.86	-0.82	0.78	0.88	0.22	0.93	-0.59	0.7	0.94	0.2	-0.25	1.0	0.97	0.75	0.94	0.86	0.15	0.88	-0.53	0.92	0.83
Total Stockholder Equity	1.0	-0.7	0.64	0.9		0.99	-0.85	0.71	0.99	0.28	0.85	-0.55	0.57	0.97	0.32	-0.29	0.9	0.97	0.71	0.96	0.91	0.12	0.89	-0.67	0.96	0.94
Property Plant And Equipment Net	0.97	-0.7	0.57	0.86	0.99		-0.85	0.72	1.0	0.24	0.8	-0.48	0.52	0.93	0.43	-0.38	0.85	0.93	0.68	0.91	0.9	0.09	0.88	-0.63	0.92	0.94
Net Debt	-0.85	0.69	-0.64	-0.82	-0.85	-0.85		-0.93	-0.85	-0.07	-0.89	0.24	-0.5	-0.81	-0.21	0.18	-0.79	-0.84	-0.72	-0.77	-0.84	0.05	-0.81	0.68	-0.77	-0.86
Cash	0.73	-0.39	0.61	0.78	0.71	0.72	-0.93		0.71	-0.08	0.83	-0.09	0.57	0.71	0.26	-0.23	0.76	0.73	0.69	0.66	0.79	-0.1	0.77	-0.42	0.67	0.76
Non Current Assets Total	0.98	-0.7	0.59	0.88	0.99	1.0	-0.85	0.71		0.26	0.81	-0.5	0.53	0.94	0.41	-0.37	0.86	0.94	0.68	0.92	0.9	0.1	0.89	-0.64	0.94	0.94
Non Currrent Assets Other	0.27	-0.3	0.12	0.22	0.28	0.24	-0.07	-0.08	0.26		0.16	-0.36	0.1	0.25	-0.23	0.14	0.23	0.28	0.16	0.29	0.22	0.03	0.23	-0.35	0.29	0.19
Cash And Short Term Investments	0.88	-0.57	0.82	0.93	0.85	0.8	-0.89	0.83	0.81	0.16		-0.46	0.55	0.84	0.06	-0.07	0.91	0.9	0.82	0.85	0.81	-0.01	0.81	-0.64	0.8	0.79
Common Stock Shares Outstanding	-0.58	0.25	-0.45	-0.59	-0.55	-0.48	0.24	-0.09	-0.5	-0.36	-0.46		-0.21	-0.58	-0.01	0.13	-0.61	-0.62	-0.19	-0.66	-0.29	-0.13	-0.31	0.34	-0.62	-0.26
Non Current Liabilities Total	0.61	-0.12	0.67	0.7	0.57	0.52	-0.5	0.57	0.53	0.1	0.55	-0.21		0.71	0.03	-0.29	0.74	0.66	0.39	0.7	0.71	0.57	0.79	-0.32	0.74	0.67
Inventory	0.98	-0.59	0.74	0.94	0.97	0.93	-0.81	0.71	0.94	0.25	0.84	-0.58	0.71		0.21	-0.25	0.94	0.98	0.65	0.98	0.9	0.22	0.91	-0.64	0.98	0.91
Other Current Assets	0.29	-0.02	-0.12	0.2	0.32	0.43	-0.21	0.26	0.41	-0.23	0.06	-0.01	0.03	0.21		-0.8	0.18	0.21	0.17	0.19	0.32	0.08	0.33	0.28	0.26	0.34
Other Stockholder Equity	-0.29	-0.03	-0.06	-0.25	-0.29	-0.38	0.18	-0.23	-0.37	0.14	-0.07	0.13	-0.29	-0.25	-0.8		-0.27	-0.23	-0.08	-0.28	-0.29	-0.27	-0.35	-0.17	-0.36	-0.3
Total Liab	0.94	-0.44	0.84	1.0	0.9	0.85	-0.79	0.76	0.86	0.23	0.91	-0.61	0.74	0.94	0.18	-0.27		0.96	0.72	0.95	0.86	0.2	0.88	-0.52	0.93	0.82
Total Current Assets	0.99	-0.6	0.76	0.97	0.97	0.93	-0.84	0.73	0.94	0.28	0.9	-0.62	0.66	0.98	0.21	-0.23	0.96		0.74	0.99	0.91	0.16	0.9	-0.64	0.97	0.9
Common Stock	0.72	-0.46	0.6	0.75	0.71	0.68	-0.72	0.69	0.68	0.16	0.82	-0.19	0.39	0.65	0.17	-0.08	0.72	0.74		0.67	0.8	-0.18	0.72	-0.43	0.6	0.74
Retained Earnings	0.97	-0.59	0.75	0.94	0.96	0.91	-0.77	0.66	0.92	0.29	0.85	-0.66	0.7	0.98	0.19	-0.28	0.95	0.99	0.67		0.89	0.26	0.89	-0.65	0.99	0.88
Net Receivables	0.92	-0.58	0.63	0.86	0.91	0.9	-0.84	0.79	0.9	0.22	0.81	-0.29	0.71	0.9	0.32	-0.29	0.86	0.91	0.8	0.89		0.2	0.96	-0.58	0.89	0.97
Intangible Assets	0.14	-0.07	0.19	0.15	0.12	0.09	0.05	-0.1	0.1	0.03	-0.01	-0.13	0.57	0.22	0.08	-0.27	0.2	0.16	-0.18	0.26	0.2		0.35	-0.15	0.31	0.22
Accounts Payable	0.91	-0.53	0.66	0.88	0.89	0.88	-0.81	0.77	0.89	0.23	0.81	-0.31	0.79	0.91	0.33	-0.35	0.88	0.9	0.72	0.89	0.96	0.35		-0.54	0.91	0.95
Short Term Debt	-0.65	0.9	-0.49	-0.53	-0.67	-0.63	0.68	-0.42	-0.64	-0.35	-0.64	0.34	-0.32	-0.64	0.28	-0.17	-0.52	-0.64	-0.43	-0.65	-0.58	-0.15	-0.54		-0.61	-0.65
Other Liab	0.97	-0.55	0.7	0.92	0.96	0.92	-0.77	0.67	0.94	0.29	0.8	-0.62	0.74	0.98	0.26	-0.36	0.93	0.97	0.6	0.99	0.89	0.31	0.91	-0.61		0.89
Net Tangible Assets	0.93	-0.68	0.6	0.83	0.94	0.94	-0.86	0.76	0.94	0.19	0.79	-0.26	0.67	0.91	0.34	-0.3	0.82	0.9	0.74	0.88	0.97	0.22	0.95	-0.65	0.89

Click cells to compare fundamentals

Ajanta Pharma Account Relationship Matchups

Ajanta Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	33.2B	37.8B	40.6B	46.8B	46.4B	48.7B
Short Long Term Debt Total	749.6M	313.6M	250.3M	356.3M	352.8M	335.2M
Other Current Liab	3.3M	1.9B	2.5B	6.6B	3.4B	3.5B
Total Current Liabilities	6.1B	6.5B	6.5B	11.4B	9.0B	9.4B
Total Stockholder Equity	26.0B	30.0B	32.6B	33.9B	35.7B	37.5B
Property Plant And Equipment Net	15.8B	16.3B	16.5B	17.0B	17.2B	18.1B
Net Debt	(1.3B)	(1.5B)	(1.8B)	(2.9B)	(942.1M)	(895.0M)
Cash	2.0B	1.8B	2.1B	3.3B	1.3B	910.1M
Non Current Assets Total	16.8B	17.5B	17.9B	18.5B	19.1B	20.0B
Non Currrent Assets Other	410.4M	566.8M	497.1M	133.4M	1.5B	1.6B
Cash And Short Term Investments	2.7B	3.8B	3.3B	8.4B	4.6B	4.8B
Common Stock Shares Outstanding	130.9M	130.6M	129.7M	128.1M	126.0M	104.9M
Liabilities And Stockholders Equity	33.2B	37.8B	40.6B	46.8B	46.4B	48.7B
Non Current Liabilities Total	1.1B	1.3B	1.4B	1.5B	1.8B	973.4M
Inventory	5.0B	7.7B	7.9B	8.2B	8.3B	8.7B
Other Current Assets	8.8B	1.4B	1.3B	1.2B	2.0B	1.8B
Other Stockholder Equity	(25.9B)	8.2B	5.3B	2.2B	(2.1B)	(2.0B)
Total Liab	7.2B	7.8B	7.9B	12.9B	10.7B	11.2B
Total Current Assets	16.4B	20.3B	22.6B	28.3B	27.3B	28.7B
Accumulated Other Comprehensive Income	(4.9B)	8.2B	5.3B	2.2B	2.3B	2.4B
Retained Earnings	16.2B	21.6B	27.2B	31.4B	35.3B	37.0B
Net Receivables	8.3B	7.4B	10.2B	10.6B	12.5B	6.5B
Intangible Assets	117.1M	107.9M	90.2M	77.5M	146.6M	95.3M
Accounts Payable	3.6B	3.7B	3.3B	4.2B	4.6B	2.8B
Short Term Debt	622.5M	115.9M	64.6M	94.3M	117.6M	111.7M
Other Liab	726.7M	1.0B	1.1B	1.3B	1.4B	1.5B
Net Tangible Assets	22.4B	25.9B	29.8B	32.6B	37.4B	21.1B
Other Assets	664.4M	1.1B	1.1B	1.1B	1.3B	797.3M
Long Term Debt	6.6M	7.4M	16M	16.4M	12.5M	0.0
Short Term Investments	671.4M	2.0B	1.2B	5.1B	3.3B	1.8B
Short Long Term Debt	449.4M	900K	2.7M	1.8M	14.9M	14.2M
Property Plant Equipment	15.8B	16.3B	16.5B	17.0B	19.5B	12.7B
Current Deferred Revenue	1.8B	2.3B	2.5B	6.8B	393.2M	373.5M
Long Term Debt Total	127.1M	197.7M	185.7M	262M	301.3M	316.4M
Net Invested Capital	26.4B	30.0B	32.7B	33.9B	35.7B	31.7B
Net Working Capital	10.4B	13.8B	16.2B	16.9B	18.4B	14.5B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Other Information on Investing in Ajanta Stock

Balance Sheet is a snapshot of the financial position of Ajanta Pharma Limited at a specified time, usually calculated after every quarter, six months, or one year. Ajanta Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ajanta Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ajanta currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ajanta Total Revenue vs Long Term Debt Analysis

Total Revenue vs Long Term Debt

Total Revenue vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Revenue

Long Term Debt

Ajanta Pharma fundamental ratios Correlations

Ajanta Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ajanta Pharma fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Ajanta Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.99	Total Stockholder Equity

Cash	- 0.93	Net Debt
Cash And Short Term Investments	- 0.89	Net Debt
Net Tangible Assets	- 0.86	Net Debt
Non Current Assets Total	- 0.85	Net Debt
Net Debt	- 0.85	Property Plant And Equipment Net
Net Debt	- 0.85	Total Stockholder Equity